Minor histocompatibilty antigens as targets for T-cell therapy after bone marrow transplantation

Current Opinion in Hematology

Volumn 5, Issue 6, 1998, Pages 429-433

  Warren, Edus H ^a   Gavin, Marc ^a   Greenberg, Philip D ^a   Riddell, Stanley R ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MINOR HISTOCOMPATIBILITY ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY GENE; HUMAN; LEUKEMIA CELL; LYMPHOCYTE CLONE; PRIORITY JOURNAL; T LYMPHOCYTE; ADOPTIVE TRANSFER; BONE MARROW TRANSPLANTATION; CELL CLONE; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; METHODOLOGY; PATHOLOGY; REVIEW;

ADOPTIVE TRANSFER; BONE MARROW TRANSPLANTATION; CLONE CELLS; GRAFT VS TUMOR EFFECT; HUMANS; IMMUNOTHERAPY; LEUKEMIA; MAJOR HISTOCOMPATIBILITY COMPLEX; T-LYMPHOCYTES;

EID: 0031593815     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199811000-00013     Document Type: Article

References (38)

1. Trowsdale J. Genomic structure and function in the MHC. Trends Genet 1993, 9:117-122.
2. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JC, et al.: Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Human Immunol 1990, 29:79-91.
3. Anasetti C, et al.: Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989, 320:197-204.
4. Nash RA, Sullivan Pepe M, Storb R, Longton G, Pettinger M, et al.: Acute graft versus-host disease: analysis of risk factors after allogeneic bone marrow transplantation and prophylaxis with cyclosporine and prednisone. Blood 1992, 80:1838-1846.
5. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
6. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, et al.: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988, 108:806-814.
7. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, et al.: Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987, 2:175-178.
8. de Bueger M, Bakker A, van Rood JJ, Van der Woude F, Goulmy E: Tissue distribution of human minor histocompatibility antigens: ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992, 149:1788-1794.
9. Riddell SR, Greenberg PD: Adoptive immunotherapy with antigen-specific T cells. In Hematopoietic Cell Transplantation. Edited by Forman SJBK, Thomas ED. Oxford: Blackwell Scientific; 1998.
10. Arnold D, Faath S, Rammensee HG, Schild H: Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 1995, 182:885-889.
11. Goulmy E, Schipper R, Pool J, Blokland E, Frederik Falkenburg JH, et al.: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996, 334:281-285.
12. Goulmy E: Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunological Rev 1997, 157:125-140. This article contains recent insights into the nature of minor H antigens and the potential use of molecular typing of minor H antigens for bone marrow donor selection and the use of minor H antigen-specific T cells for adoptive immunotherapy of leukemia.
13. + CTL specific for minor H antigens with a restricted distribution of tissue expression can be isolated from the majority of allogeneic BMT recipients and identifies a large number of previously undefined specificities, including an H-Y antigen that is selectively expressed on hematopoietic cells. These results suggest that adoptive immunotherapy to promote GVL activity should be feasible in the majority of patients.
14. Scott DM, Ehrmann IE, Ellis PS, Bishop CE, Agulnik AI, Simpson E, Mitchell MJ: Identification of a mouse male-specific transplantation antigen, H-Y. Nature 1995, 376:695-698.
15. Wang W, Meadows LR, den Haan JM, Sherman NE, Chen Y, Blokland E, et al.: Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995, 269:1588-1590.
16. Meadows L, Wang W, den Haan JM, Blokland E, Reinhardus C, Drijfhout JW, et al.: The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 1997, 6:273-281. This study demonstrates that T cells specific for a determinant from the SMCY gene only recognize a posttranslationally altered form of the SMCY peptide. This is the second example of posrtranslational modification of a class I epitope, and it illustrates an advantage of using the peptide elution strategy for directly identifying minor H determinants.
17. Lahn BT, Page DC: Functional coherence of the human Y chromosome. Science 1997, 278:675-680.
18. Goulmy E: Minor histocompatibility antigens from T cell recognition to peptide identification. Human Immunol 1997, 54:8-14.
19. van Els CA, D'Amaro J, Pool J, Blokland E, Bakker A, van Elsen PJ, et al.: Immunogenetics of human minor histocompatibility antigens: their polymorphism and immunodominance. Immunogenetics 1992, 35:161-165.
20. + CTL clone specific for a novel minor H antigen presented by HLA B44 and with an allele frequency of 28% in B44-positive individuals are described. Using CTL assays, expression of HB-1 is detected in transformed B cells, including ALL but not resting B cells or other hematopoietic and nonhematopoietic cells. HB-1 is suggested as a potential target for immunotherapy of ALL after allogeneic BMT.
21. Morse MC, Bleau G, Dabhi VM, Hetu F, Drobetsky EA, Lindahl KF, Perreault C: The COI mitochondrial gene encodes a minor histocompatibility antigen presented by H2-M3. J Immunol 1996, 156:3301-3307.
22. Bhuyan PK, Young LL, Lindahl KF, Butcher GW: Identification of the rat maternally transmitted minor histocompatibility antigen. J Immunol 1997, 158:3753-3760.
23. King TR, Christianson GJ, Mitchell MJ, Bishop CE, Scott D, Ehrmann I, et al.: Deletion mapping by immunoselection against the H-Y histocompatibility antigen further resolves the Sxra region of the mouse Y chromosome and reveals complexity of the Hya locus. Genomics 1994, 24:159-168.
24. Gubarev MI, Jenkin JC, Leppert MF, Buchanan GS, Otterud BE, Guilbert DA, Beatty PG: Localization to chromosome 22 of a gene encoding a human minor histocompatibility antigen. J Immunol 1996, 157:5448-5454.
25. Hunt DF, Henderson RA, Shabanowitz J, Sakaguchi K, Michel H, Sevilir N, et al.: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectometry. Science 1992, 255:1261-1263.
26. den Haan JMM, Sherman NE, Blokland E, Huczko E, Koning F, Wouter Drijfhout J, et al.: Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995, 268:1476-1480.
27. den Haan JMM, Meadows LM, Wang W, Pool J, Blokland E, Bishop TL, et al.: The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998, 279:1054-1057. This study describes the identification of the HA1 gene using the peptide elution methodology. HA1 is encoded by a diallelic gene differing in the nonamer epitope by a single amino acid. This finding will now permit a determination of the tissue expression of the gene and should assist in resolving the surprising association of HA1 with GVHD.
28. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 1994, 12:337-365.
29. b alleles accounts for self/nonself discrimination at this locus.
30. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Restoration of cellular immunity against CMV in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
31. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, et al.: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med 1996, 2:551-555.
32. Falkenburg JH, Goselink HM, van der Harst D, van Luxemburg-Heijs SA, Kooy-Winkebar YM, Faber LM, et al.: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991, 174:27-33.
33. van der Harst D, Goulmy E, Falkenburg JH, Kooij-Winkelaar YM, van Luxemburg-Heijs SA, Goselink HM, Brand A: Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994, 83:1060-1066.
34. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 1997, 3:730-737. This study examines the phenotype and frequency of a putative AML stem cell by engraftment of NOD/SCID mice. This model provides an opportunity to assess the effect on leukemic stem cells of therapeutic interventions, including T cells directed against minor H antigens.
35. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al.: A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994, 367:645-648.
36. Appelbaum FR: Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncology 1997, 24:114-123.
37. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, et al.: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997, 276:1719-1724. The infusion of unselected polyclonal donor lymphocytes to treat leukemic relapse or Epstein-Barr virus-associated lymphoproliferative disorders after BMT often results in GVHD disease. In this study, the HSV-TK gene was introduced into donor lymphocytes before infusion so that ganciclovir could be used to eliminate the infused T cells and ameliorate GVHD. This approach could provide a general safety strategy for immunotherapy with T cells in settings where toxicity is a potential outcome.
38. + HIV-specific cytotoxic T lymphocytes in HIV infected subjects. Nature Med 1996, 2:216-223.